MHRA Alert – Fezolinetant (Veoza): Liver Injury Risk & Monitoring Guidance

Drug Safety Update: Fezolinetant (Veoza)

The MHRA has issued new safety recommendations for fezolinetant (Veoza) following reports of drug-induced liver injury in patients receiving this treatment. Healthcare providers should be aware of this risk and implement appropriate monitoring protocols.

Key Points

• Fezolinetant treatment carries a documented risk of drug-induced liver injury
• New recommendations have been introduced to identify and minimise this risk
• Liver function monitoring is now mandatory before and during treatment in all patients
• Clinicians should review current patient management in light of these new guidelines

Affected Medication

• Fezolinetant (Veoza)

Recommended Actions

All healthcare providers prescribing or managing patients on fezolinetant should:

• Review the full MHRA safety alert for detailed monitoring recommendations
• Ensure baseline liver function tests are performed before initiating treatment
• Establish a schedule for ongoing liver function monitoring during therapy
• Discuss the risks and benefits with patients, particularly those with pre-existing liver disease
• Report any suspected adverse reactions via the Yellow Card scheme

Further Information

For the complete safety update and detailed clinical guidance, visit the MHRA Drug Safety Update page.